Side-by-side · Research reference
LivagenvsSelank
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/32 cited
BHuman-MechanisticAUTO-DRAFTED11/40 cited
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
Selank
Anxiolytic + Cognitive · Russian Pharma
Intranasal · 2–3×/day during stress / cognitive demand
01Mechanism of Action
Parameter
Livagen
Selank
Primary target
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Pathway
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
Downstream effect
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Origin
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Antibody development
—
—
02Dosage Protocols
Parameter
Livagen
Selank
Animal dose (oral)
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
—
Duration (experimental)
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
—
Route
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
—
Evidence basis
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Human-mechanistic + Russian clinical trialsMedvedev 2007
Human data
None in provided literature
—
Frequency
—
2–3× per day during stress
Lower / starter dose
—
75 mcg / dose
Duration
—
10–14 day cycles, repeated as needed
Reconstitution
—
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
—
Morning + early afternoon preferred
Half-life
—
Short (minutes plasma); CNS effect lasts ~3 hr
04Side Effects & Safety
Parameter
Livagen
Selank
Reported adverse effects
None documented in animal studies
—
Human safety data
No human trials in provided literature
—
Nasal irritation
—
Mild burning or congestion (transient)
Cognitive impairment
—
None — opposite effect (enhancement)
Allergic reaction
—
Rare hypersensitivity
Long-term safety
—
Limited Western RCT data
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
Livagen
—Selank
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Relative Contraindications
Livagen
—Selank
- ·Active autoimmune disease (theoretical via immunomodulation)
05Administration Protocol
Parameter
Livagen
Selank
1. Route selection
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Timing
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
3. Age-dependent response
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
4. Storage
—
Refrigerate after reconstitution; ≤30 days. Light-protected.
5. Caveat
—
Avoid co-administration with strong sedatives or other anxiolytics initially.